已收盘 12-12 16:00:00 美东时间
+0.010
+0.91%
Gainers Xenetic Biosciences (NASDAQ:XBIO) stock rose 10.2% to $2.8 during Wedn...
11-20 05:07
BioRestorative Therapies (NASDAQ:BRTX) reported quarterly losses of $(0.33) per share which beat the analyst consensus estimate of $(0.36) by 8.33 percent. This is a 153.85 percent decrease over losses of $(0.13) per
11-13 05:14
<p>BioRestorative Therapies, Inc. reported its third-quarter 2025 financial results and provided updates on its operations. The company highlighted a registered direct offering in October, which strengthened its financial position. It also announced an intellectual property milestone with the Japanese Patent Office issuing a notice of allowance for its ThermoStem® platform. Crystal Romano was appointed as Head of Global Commercial Operations. The...
11-12 21:05
Companies Reporting Before The Bell • Hudbay Minerals (NYSE:HBM) is projected t...
11-12 19:11
BioRestorative Therapies (NASDAQ:BRTX) is preparing to release its quarterly ea...
11-12 02:02
BioRestorative Therapies, Inc. (BRTX) will release its third quarter 2025 financial results after market close on November 12, 2025. Management will host a conference call at 4:30 p.m. ET to discuss the results. The call will be accessible via 1-888-506-0062 (domestic) or 1-973-528-0011 (international) with access code 464585. BRTX focuses on stem cell-based therapies for disc/spine disease, metabolic disorders, and aesthetic products.
11-05 21:30
BioRestorative Therapies, Inc. (NASDAQ: BRTX) announced that the Japanese Patent Office has granted a Notice of Allowance for its ThermoStem® platform, covering allogeneic, off-the-shelf brown adipose-derived stem cell (BADSC) technology for treating obesity and metabolic disorders. The patent provides broad protection for therapeutic cells and multiple delivery methods, positioning BRTX to develop next-generation alternatives to GLP-1 drugs. The...
10-27 11:30
BioRestorative Therapies, Inc. (BRTX) announced the appointment of Crystal Romano to its management team, where she will lead global commercial operations and innovation. With over 19 years of experience in medical, aesthetics, and regenerative industries, Romano brings expertise in product development, commercialization, and FDA regulations. She joins at a pivotal time for the company, which focuses on stem cell-based therapies for treating disc...
10-22 13:35
BioRestorative Therapies, Inc. (NASDAQ:BRTX) will participate in the 2025 Maxim Growth Summit, where CEO Lance Alstodt and VP Francisco Silva will discuss stem cell therapy's potential in a panel. The company will also engage with institutional investors. BRTX specializes in stem cell-based therapies for disc/spine disease, metabolic disorders, and aesthetic products. Its programs include BRTX-100 for disc disease, ThermoStem® for metabolic condi...
10-15 13:35
BioRestorative Therapies ( ($BRTX) ) has shared an announcement. On October 6, ...
10-09 05:28